Volume 10 Supplement 1

de Senectute: Age and Health Forum

Open Access

Chronic venous insufficiency strengthens the thrombo-embolic risk in congestive heart failure in elderly patients

  • F Ciciarello1,
  • S Mandolesi1,
  • D Mandolesi1,
  • G D’Ambrosio1 and
  • F Fedele1
BMC Geriatrics201010(Suppl 1):A52

https://doi.org/10.1186/1471-2318-10-S1-A52

Published: 19 May 2010

Background

As for other pathologies, the pathogenesis of venous thrombo-embolism (VTE) is multifactorial. A comprehensive understanding of the pathogenesis of venous thrombosis is essential for identifying patients at increased risk as in elderly patients with congestive heart failure (CHD) and with presence of chronic venous insufficiency (IVC). Eberhard Mammen postulated immobility as the leading event in the CHD , because it reduced blood flow as a result of decreased muscle contraction. The subsequent "stasis of flow" led to accumulation of blood within the intramuscular sinuses, especially of the calf, triggering hypercoagulability due to local accumulation of activated clotting factors and coagulation activation products and the simultaneous consumption of blood coagulation inhibitors.

Materials and methods

We have analyzed, in the latest years, the results of a comprehensive examination of 214 elderly (Group 1; aged 71+/12 years) hospitalized with CHD and 187 patients (Group 2; aged 76+/-9 years) with CHD and venous disorders (CVI) in class C2/3/C4 according to the CEAP classification (detected by systematic compression ultrasound and hemodynamic venous mapping). We randomized our study population Groups 2 in three Subgroup , admit to hospital, to receive : A ) 33 pts. fondaparinux sodium, 2,5 mg/0,5 ml , B) 45 pts. enoxaparin sodium 40 mg /0,4ml, C ) 111 pts. receiving other therapy.

Results

We have observed a minor incidence of venous thrombo-embolism (DVT) in Group 1 ( that receiving for 45% LMWH and the remaining other) respectively the total Group two, as shown in Table 1, with a significant increase in thrombo-embolic risk, especially in the Subgroup C ( absence LMW).

Table 1

 

N. pts.

Aged

DVT

EP

P<

Group 1 (CHD)

214

71+/12years

5,14 % (11case)

1 case

 

Group2 (CHD/IVC)

187

76+/-9 years

8,5 % (16 case)

1 case

0,01

Subgroup A

33

72+/-4 years

3 % (1 case)

  

Subgroup B

45

74+/-6 years

2,2 % (1 case)

  

Subgroup C

111

75+/-9 years

12,6 % (14 case)

1 case

0,01

Conclusions

IVC is a disease of great social impact , certainly underestimated by the medical profession itself, also to its consequences. Therefore, we believe that in agreement with the major trials ( Medenox, ecc.) IVC is a disease that strengthens the trombo-embolic risk comorbidity in CHD.

Authors’ Affiliations

(1)
Cardiovascular Department, Sapienza University of Rome

Copyright

© Ciciarello et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement